A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Overview

About this study

The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of ABBV-383. In Part 2, the step-up dose identified in Part 1 will be used followed by the target dose of ABBV-383. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Must have measurable disease as outlined in the protocol.

- Eastern Cooperative Oncology Group (ECOG) performance of <= 2.

- Relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of
progression during or after the participant's last treatment regimen based on the
investigator's determination of the International Myeloma Working Group (IMWG) 2016
criteria.

- Must be naïve to treatment with ABBV-383.

- Arm A: Must have received at least 3 or more lines of therapy, including a proteasome
inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal
antibody.

- Arm B: Must have received at least 2 or more lines of therapy, including exposure to a
PI, an IMiD, an anti-CD38 monoclonal antibody, and a prior B-cell maturation antigen
(BCMA)-targeted therapy (anti-drug conjugate [ADC] or chimeric antigen receptor T-cell
[CAR-T] directed against BCMA).

Exclusion Criteria:

- Arm A: Received BCMA-targeted therapy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/8/24. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Saurabh Chhabra, M.B.B.S.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20547586

Mayo Clinic Footer